The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


Published online August 5, 2009
The Journal of Immunology, 2009, 183, 2957 -2965
Copyright © 2009 by The American Association of Immunologists, Inc.
doi:10.4049/jimmunol.0900508

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jimmunol.0900508v1
183/5/2957    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Oliveira, A. L. A.
Right arrow Articles by Hall, W. W.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Oliveira, A. L. A.
Right arrow Articles by Hall, W. W.

High Frequencies of Functionally Competent Circulating Tax-Specific CD8+ T Cells in Human T Lymphotropic Virus Type 2 Infection

André L. A. Oliveira*, Hitoshi Hayakawa*, Doris Schor{ddagger}, Ana Claudia C. B. Leite§, Otávio M. Espíndola{ddagger}, Allison Waters{dagger}, Jonathan Dean*, Derek G. Doherty,||, Abelardo Q.-C. Araújo*,§ and William W. Hall1,*,{dagger}

* Centre for Research in Infectious Diseases and {dagger} National Virus Reference Laboratory, University College Dublin, Dublin, Ireland; {ddagger} Viral Pathogenesis Research Laboratory and § Laboratory for Research in Neuroinfections, Evandro Chagas Institute for Clinical Research, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil; Cellular Immunology Laboratory, Department of Biology, National University of Ireland, Maynooth, Ireland; and || Department of Immunology, Trinity College Dublin, St. James’s Hospital, Dublin, Ireland

Human T lymphotropic virus type 2 (HTLV-2) is characterized by a clinically asymptomatic persistent infection in the vast majority of infected individuals. In this study, we have characterized for the first time ex vivo specific CTL responses against the HTLV-2 Tax protein. We could detect CTL responses only against a single HLA-A*0201-restricted Tax2 epitope, comprising residues 11–19 (LLYGYPVYV), among three alleles screened. Virus-specific CTLs could be detected in most evaluated subjects, with frequencies as high as 24% of circulating CD8+ T cells. The frequency of specific CTLs had a statistically significant positive correlation with proviral load levels. The majority of virus-specific CD8+ T cells exhibited an effector memory/terminally differentiated phenotype, expressed high levels of cytotoxicity mediators, including perforin and granzyme B, and lysed in vitro target cells pulsed with Tax2(11–19) synthetic peptide in a dose-dependent manner. Our findings suggest that a strong, effective CTL response may control HTLV-2 viral burden and that this may be a significant factor in maintaining persistent infection and in the prevention of disease in infected individuals.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 Address correspondence and reprint requests to Prof. W. Hall, The Centre for Research in Infectious Diseases, University College Dublin, Belfield, Dublin 4, Ireland. E-mail address: william.hall{at}ucd.ie

2 Abbreviations used in this paper: HTLV, human T lymphotropic virus; ATLL, adult T cell leukemia/lymphoma; HAM/TSP, HTLV-1-associated myelopathy/tropical spastic paraparesis; PD-1, programmed death 1; PVL, proviral load; TCM, central memory T cell; TEM, effector memory T cell; TEMRA, terminally differentiated memory T cell; TN, naive T cell.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2009 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2009 by The American Association of Immunologists, Inc. All rights reserved.